David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Welcome and Introduction to Vi3C

May

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Welcome and Introduction to Vi3C

FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer

Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy

Association of Body Size and Bladder Cancer Risk

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Can PFAS Exposure Raise ALL Risk?